Characterization of protein marker expression, tumorigenicity, and doxorubicin chemoresistance in two new canine mammary tumor cell lines
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1746-6148
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Characterization of protein marker expression, tumorigenicity, and doxorubicin chemoresistance in two new canine mammary tumor cell lines ; volume:10 ; number:1 ; day:30 ; month:9 ; year:2014 ; pages:1-9 ; date:12.2014
BMC veterinary research ; 10, Heft 1 (30.9.2014), 1-9, 12.2014
- Creator
-
Hsiao, Yen-Ling
- Contributor
-
Hsieh, Tai-Zu
Liou, Chian-Jiun
Cheng, Yeong-Hsiang
Lin, Chung-Tien
Chang, Chi-Yao
Lai, Yu-Shen
SpringerLink (Online service)
- DOI
-
10.1186/s12917-014-0229-0
- URN
-
urn:nbn:de:1111-2016080554194
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hsiao, Yen-Ling
- Hsieh, Tai-Zu
- Liou, Chian-Jiun
- Cheng, Yeong-Hsiang
- Lin, Chung-Tien
- Chang, Chi-Yao
- Lai, Yu-Shen
- SpringerLink (Online service)
Other Objects (12)
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines
Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas
Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
Comparative mammary oncology: canine model
An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells
Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53
Current biomarkers of canine mammary tumors
Estrogen receptors genotypes and canine mammary neoplasia
Global protein analyses of canine mammary gland tumors
Significance of EZH2 expression in canine mammary tumors
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines
Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas
Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
Comparative mammary oncology: canine model
An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells
Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53
Current biomarkers of canine mammary tumors
Estrogen receptors genotypes and canine mammary neoplasia
Global protein analyses of canine mammary gland tumors
Significance of EZH2 expression in canine mammary tumors
Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines
Expression of prolactin receptors in normal canine mammary tissue, canine mammary adenomas and mammary adenocarcinomas
Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection
Comparative mammary oncology: canine model
An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells
Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53
Current biomarkers of canine mammary tumors
Estrogen receptors genotypes and canine mammary neoplasia
Global protein analyses of canine mammary gland tumors